ArticleBMJ open2023

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.

Wei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.